• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Namenda: Pining for Another Indication

Namenda: Pining for Another Indication

August 1, 2005
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue
Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.

In 2003, the FDA approved Namenda (memantine) as a treatment for moderate to severe Alzheimer’s Dementia (AD). Backed by the legendary marketing expertise of Forest Labs, the medication has become remarkably popular, gradually eating into the market share of the cholinesterase inhibitors (CIs). The question, as always, is whether this popularity is justified by the data.

Recently, a meta-analysis was published by the Cochrane Collaborative reviewing pretty much everything that we know about Namenda to date (http://www.mrw.interscience.wiley. com/cochrane/clsysrev/articles/CD003154/frame.html, accessed 6/30/05), including nine published and three unpublished studies. For those who don’t know, the Cochrane reviews are considered the international “gold standard” in evidence-based health information.

Let’s look first at how robust the data is for Namenda’s only official FDA indication, moderate to severe Alzheimer’s dementia. The standard research definition of “moderate to severe dementia” is an MMSE score below 15; in the two Namenda studies, the average MMSE of participants ranged from 8 to 10 (NEJM, 2003; 348:1333-1341, and JAMA, 2004; 291:317-324). This is a level of impairment that most of us are unlikely to see in our offices, unless we specialize in dementia treatment. According to the study authors, these patients typically required assistance with basic ADLs, such as bathing and dressing, and many were incontinent.

In this population, Namenda 20 mg QD was statistically superior to placebo in measures of cognition, ADLs, and agitation, but the effect sizes, in all cases, were “small or very small,” according to the reviewers. The primary cognitive measure in these studies, the “SIB,” is a scale ranging in score from 0-100; the average improvement over placebo in the two trials was 4 SIB points, unlikely to yield a clinically significant improvement, particularly in such an impaired population.

There also exists a mysterious third Namenda study, named “MD-01” by Forest, but it hasn’t yet been published, even though the study was completed in June of 2003. Such a long lag in study publication is generally diagnostic of unfavorable results, leading the Cochrane reviewers to conclude that the published results may overestimate the effectiveness of Namenda (this phenomenon is known as “publication bias”). TCR urges you to nudge your Forest reps about the MD-01 results next time you see them!

What about Namenda for mild to moderate dementia? Just as we were about to go to press with this issue, Forest announced that the FDA rejected Namenda’s application for approval for mild dementia, which was no surprise to those who had looked at the data. No studies of Namenda for mild to moderate AD have been published. One study, presented as a poster, showed a small benefit over placebo, but the two other studies yielded no significant effects, according to the Cochrane review.

Data or not, Forest has found a creative way to produce a mild-dementia “halo effect” around Namenda. They did this by funding a study in which 404 patients with moderate to severe AD, all of whom had been taking Aricept for about two years, were randomized to receive add-on Namenda vs. add-on placebo. The Namenda group did a little bit better than the placebo group after six months (JAMA, 2004; 291:317-324). While Forest can officially use this study only to promote Namenda for moderate to severe AD, the fact that it was added to a drug only approved for mild to moderate AD (Aricept) has the effect of planting a seed in our minds that Namenda might be effective for both indications. Talk about subliminal advertising!

TCR VERDICT: Namenda: A small effect for the most impaired.
General Psychiatry
    Carlat 150x150
    Daniel Carlat, MD

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)

    More from this author
    www.thecarlatreport.com
    Issue Date: August 1, 2005
    SUBSCRIBE NOW
    Table Of Contents
    The Man Behind Alzheimer’s Disease
    Marc Agronin, M.D., on Treating Agitation in Dementia
    Rosack’s FDA Watch: Atypical Antipsychotics and the Elderly
    Namenda: Pining for Another Indication
    Cholinesterase Inhibitors: Under Siege
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.